Pharma Medical News about biotechnological drugs

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Position statement of the Portuguese Society of Nephrology on the clinical use of biotechnological drugs in renal patients
Portuguese Journal of Nephrology and Hypertension, 10/12/09

Luz–Rodrigues H et al. – The Expert Panel of the Portuguese Society of Nephrology believes that the safeguard of therapeutic value and safety aspects are mandatory, particularly in biotechnology drugs prescribed for long periods of time. The Panel also believes there is no absolutely safe interchangeability of bioproducts, and that if changes are required this must in all instances be decided by a medical doctor based on solid scientific and clinical data. In this area, financial issues shall on no occasion introduce additional risks to the patient or overcome medical prescription.

<< Previous
Cardiac Cell Repair Therapy: A Clinical Perspective

Next >>
How Do Physicians Conduct Medication Reviews

Psychotropic Drug Use During Breastfeeding: A Review of the Evidence
Pediatrics, 10/01/09 Relevance Score: 49%

An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists
Clinical Therapeutics, 10/15/09 Relevance Score: 48%

Online Illegal Drug Use Information: An Exploratory Analysis of Drug-Related Website Viewing by Adolescents
Journal of Health Communication, 10/29/09 Relevance Score: 47%

Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain
AIDS Research and Human Retroviruses, 10/23/09 Relevance Score: 46%

Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
Journal of Clinical Oncology, 10/16/09 Relevance Score: 46%